İdrardan İzole Edilen Mantarların Türlere Göre Dağılımı Ve Antifungal Duyarlılıklarının Araştırılması

Öz

Bu çalışmada 2121 idrar örneğinden izole edilen 95 adet mantarın % 4.5 dağılımı ve bunların antibiyotikduyarlılıkları API ID 32C ve ATB fungus kitleri bioMérieux kullanılarak araştırıldı ve sonuçlar API bioMérieux sistemiyle tespit edildi. 58 kandida türünün %61.1 dağılımı şöyle olmuştur: Candida tropicalis %13.7 , Candidaalbicans %10.6 , Candida intermedia %9.5 , Candida krusei %7.4 , Candida catenulata %5.3 , Candidainconspicua 4.2 , Candida parapsilosis %4.2 , Candida sake %3.2 , Candida humicole %3.2 . Diğer 37 fungus %38.9 ise şöyle dağılmıştır: Tricophyton cutaneum %15.8 , Debaryomyces merome %16.3 , Pichia farinosa %6.3 , Cryptococus albidus %3.2 , Cryptococcus laurentii %3.2 , Saccharomyces cerevisiae % 3 . 2 ,Saccharomyces kluyverii %1.1 .5-flusitosin, amfoterisin B, nistatin, mikonazol, ketakonazol ve ekonazol arasında en etkili antibiyotik %2 dirençoranıyla 5-flusitosin’dir. Bununla birlikte direnç oranı diğer antifungallere karşı %17-%29 arasında bulundu.Kandida hariç diğer türler bu çalışmada kullanılan antifungallere karşı %14-%30 arasında dirençli bulunmuştur

Anahtar Kelimeler

• Kandida türleri, antifungal duyarlılık, API

Distribution Of Fungi Isolated From Urine And Investigation Of Antifungal Susceptibility

Abstract

In this study, distrubution of 95 fungi 4.5% isolated from 2121 urine specimens and their antibioticsusceptibility were investigated by using API ID-32- C and ATB fungus kits bioMérieux and results were determinedby API system bioMérieux . Distribution of 58 611 % candida species are as: Candida tropicalis 37.7% ,Candida albicans 10.6% , Candida intermedia 9.5% , Candida krusei, 7.4% , Candida catenulata 5.3% ,Candida inconspicuaand Candida parapsilosis 4.2% species, Candida sakeand Candida humicola 3.2% other37 fungu 38.9% are as: Trichopyton cutaneum 15.8% Debaryomyces maromeand Pichia farinosa 16.3% ,Cryptococcus albidus,Cryptococcus lauranti-Sacchoromyces cerevisiae 3.2 % and Sacchoromyces kluyverii 1.1% .The most effective antibiotic among 5-flucytosine, amphotericine B, nystatine, miconazole, ketoconazole andeconazole is 5 flucytosine with 2 % resistance rate. However resistance rate was detected between 17%-29%against other antibiotics. Other species except candida have been found resistant between 14% and 30% againstantibiotics used in this study

Keywords

• Candida species, antifungal susceptibility, API

Kaynakça

1. Horowitz BJ. Antifungal therapy in the management of chronic candidiasis. Am J Obstet Gynecol, 1988;158: 992.
2. Simor AE, Goswell G, Louie L, Lee M and Louie M. Antifungal susceptibility testing of yeast isolates from blood cultures by Microbroth dilution and the E test. Eur J Clin Microbiol Infect Dis, 1997; 16: 693-699.
3. Kwon C, Chung KJ and Bennet JE. Medical Mycology. Lea-Febiger. Philadelphia-London 1992.
4. Perera J and Clayton Y. Incidence, species distribution and antifungal sensitivity pattern of vaginal yeasts in Sri Lankan women. Mycoses, 1994; 37 (9-10): 357-362.
5. Arias A, Arevalo MP, Andreu A, Rodriguez C, Sierra A. Candida glabrata: in vitro susceptibility of 84 isolates to eight antifungal agents. Chemotherapy, 1996; 42 (2): 107-11.
6. Denning DW, Baily GG and Hood SW. Azole resistance in Candida. Eur J Clin Microbiol Infect Dis, 1997; 16: 280
7. Espinel A, Kerkering TM , Goldson PR and Shadomy S. Comparison study of broth macrodilution and mikrodilution antifungal susceptibility tests. J Clin Microbiol, 1991; 29: 189-197.
8. Odds F C. Commensalism and Pathogenicity of Yeasts on Skin. J Med Microbiol, 1984; 17: 8.

9. Odds FC, Milne LJR, Getles JC and Ball EH. The activity in-vitro and in-vivo of a new imidazole antifungal, ketoconazole. J Antimicrob Chemother, 1980; 6: 97-105.
10. Demirel AH. Enstitümüzde İzole Edilen Candida' lar Üzerinde Bir Çalışma, Uzmanlık Tezi, GATA, 1976.
11. Erol N. Vagen Florasındaki Candida Türlerinin Dağılımı ve Antifungallere Duyarlılığı. Uzmanlık Tezi, Ankara, Bahukova TA, Dobrodeeva LK. Role of fungi belonging to the genus Candida in the etiology of nonspecific pulmonary diseases. Antibiot Chemother, 1996; 41 (6):44-8 .
12. Fan-Havard P, Capano D, Smith SM, Mangia A and Eng RH. Development of resistance in candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother, 1991; 35 (11): 2305.
13. Gürer SÜ, Çevikbaş A, İmamoğlu Ç, Daşdelen N, Yıldırım A, Derici K. Vajinitli hastalardan izole edilen maya türlerinin antifungallere duyarlılıkları. ANKEM Derg, 1997; 11 (4): 482-486.
14. Kaya D ve Kiraz N. Vajinal örneklerden izole edilen maya türlerinin bazı antifungal maddelere duyarlılıkları. Mikrobiyol Bült, 1994; 28: 352-358.
15. Kunzelmann V, Tietz HJ, Rossner D, Czaika V, Hopp M, Schmalreck A and Sterry W. Prerequisites for effective therapy of chronic recurrent vaginal candidiasis Mycoses, 1996; 39 (1): 65-72.
16. Billie J, Glauser MP and the Fluconazole Global Susceptibility Study Group. Evaluation of the susceptibility of pathogenic Candida species to Fluconasole Eur J Clin Microbiol Infect Dis, 1997; 16 : 924-928.
17. Favel A, Michel-Nguyen A, Chastin C, Trousson F, Penaud A and Regli P. In-vitro susceptibility pattern of Candida lusitaniae and evaluation of the E test method. J. Antimicrob Chemother, 1997; 39 (5): 591-596.
18. Arıkan S, Gür D ve Akova M. Klinik önem taşıyan Candidatürlerinin antifungal ajanlara in-vitro duyarlılıkları. ANKEM Derg, 1995; 9 (2) : 139.
19. Azimi J, Aktan G ve Uzun M. Tırnak infeksiyonu olan mayalar ve antifungal maddelere duyarlılıkları. ANKEM Derg, 1995; 9 (1): 63-69.
20. Carrilo-Munoz AJ, Tur C and Torres J. In-vitro antifungal activity of sertaconazole, bifonazole, ketoconazole, and miconazole against yeasts of the Candida genus. J Antimicrob Chemother, 1996; 37 (4): 815-819.